secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jaguar Health, Inc. (JAGX)
CIK:        0001585608
Form:       8-K
Filed at:   2026-05-27T13:10:06+00:00
Accession:  0001193125-26-240645
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jaguar Health regains Nasdaq Bid Price compliance; monitoring until May 2027
----------------------------------------------------------------------------

- Formal notice from Nasdaq on May 26, 2026: Jaguar complies with Bid Price Rule (closing bid ≥$1/sh).
- Panel maintains jurisdiction until Sept 1, 2026; Mandatory Panel Monitor imposed until May 26, 2027.
- If bid price <$1 for 30 consecutive trading days during monitoring, no 180-day grace period; delisting possible.
- CEO Lisa Conte reported Q1 2026 net revenue +816% YoY and +527% QoQ, driven by out-license with Future Pak.
- Company targets NDA for crofelemer formulation in mid-2027 and seeks development/commercialization partner.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1585608/000119312526240645/0001193125-26-240645-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1585608/000119312526240645/d129501d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-240645

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer